GW Pharmaceuticals Gains NHS Approval for Epidyolex and Sativex

GW Pharmaceuticals [stock_market_widget type="inline" template="generic" color="default" assets="GWPH" markup="(NASDAQ: {symbol} {currency_symbol}{price} ({change_pct}))" api="yf"] is celebrating after the British government approved two of its products for NHS prescriptions.

The National Institute for Health and Care Excellence (Nice) has issued new guidance that allows local NHS Trusts to fund prescriptions of Epidyolex and Sativex. The landmark decision reverses previous guidance that said Sativex was too expensive in relation to the benefits it provides.

Patient groups are extremely pleased that people in the UK can now gain access to Sativex, an oral spray containing THC and CBD. Local NHS authorities can now pay for a four-week trial for anyone with moderate to severe muscle spasticity brought on by MS, and if symptoms reduce by at least 20% the patient can continue taking it.

Epidyolex recently gained EU approval and it is also the only medical cannabis product to gain FDA approval in the U.S., where it is registered as Epidiolex. It is prescribed for people suffering from rare forms of epilepsy: Lennox-Gastaut and Dravet syndromes.

GW Pharma is based in the UK and it said it was proud to offer this in the country where the company was founded and where both of these medicines were developed and are manufactured. Nice was previously skeptical about medical cannabis products, but GW Pharma passed rigorous tests to prove the efficacy of Epidyolex and Sativex.

“This is a momentous occasion for UK patients and families who have waited for so many years for rigorously tested, evidenced and regulatory approved cannabis-based medicines to be reimbursed by the NHS,” said Chris Tovey, GW’s chief operating officer.

The firm is also working with the relevant bodies in Germany, Spain, France, and Italy to secure reimbursement ahead of the anticipated launch of the medicine in those countries. It has submitted a bid to gain FDA approval for Sativex in the U.S.

GW reported its Q3 financials on Tuesday last week and posted a net loss of $13.8 million, a significant improvement on the $79.9 million it lost during the same period in 2018. Sales of Epidiolex in the U.S. also beat analysts’ estimations, but the firm’s share price decreased dramatically over fears that sales could plateau.

However, it is now seeing new markets open up and it looks like an interesting stock to watch as it bids to demonstrate increased profitability in the months ahead.

0 0 votes
Article Rating

The opinions provided in this article are those of the author and do not constitute investment advice. Readers should assume that the author and/or employees of Capital 10X hold positions in the company or companies mentioned in the article. For more information, please see our Content Disclaimer.

Martin Green
Martin Green is an experienced journalist with a strong focus on the cannabis, alcohol, and gambling industries. He is particularly interested in the political issues affecting the global marijuana trade, and he has a keen focus on regulation changes and legal topics. He holds a BA English Literature, MA Creative Writing and a National Qualification in Journalism diploma. He has worked in journalism since 2009 and written for a broad range of newspapers, business titles and magazines, including The Sun, The Metro, The Journal, Livestrong, Drinks Retailing News, Harpers, Sportsbook Review, Vital Football, Essex Live and Surrey Live. Address: 682 Indian Road, Toronto, Ontario, M6P 2C9. Phone: 416-721-8257.
Notify of
Inline Feedbacks
View all comments